CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL
Rebecca Epperly(St. Jude Children's Research Hospital), Aimee C. Talleur(St. Jude Children's Research Hospital), Asim K. Bag(St. Jude Children's Research Hospital), Swati Naik(St. Jude Children's Research Hospital), Stephen Gottschalk(St. Jude Children's Research Hospital), Barry L. Shulkin(St. Jude Children's Research Hospital), Hiroto Inaba(St. Jude Children's Research Hospital), Brandon M. Triplett(St. Jude Children's Research Hospital), Cheng Cheng(Jilin University), John T. Lucas(Wake Forest University)
Cited by 9
Related Papers
Evidence for 28 genetic disorders discovered by combining healthcare and research data
|Nature|2020|672
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
|Journal of Clinical Oncology|2010|648
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
|The Lancet Oncology|2010|586
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
|Nature Genetics|2016|473
Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia
|Journal of Clinical Oncology|2014|390